Editors’ Picks: November Highlights from the AACR Journals
With Thanksgiving behind us here in the United States, the holiday season is in full swing. So, grab some...
With Thanksgiving behind us here in the United States, the holiday season is in full swing. So, grab some...
We asked experts in cancer precision medicine, immunotherapy, and prevention what breakthroughs we might expect to see in 2016...
Next-generation genome analysis technologies allow for the sequencing of multiple genes at once to characterize the mutational profile of...
This year marks the 10th anniversary of Cancer Discovery, a journal of the AACR. To celebrate the anniversary, Cancer Discovery published a special anniversary issue, featured spotlights on groundbreaking articles on its website, and held the Cancer Discovery ...
In 2018, we witnessed significant momentum in several hot areas of cancer research, including immunotherapy and precision medicine. Researchers...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today In his 2016 State of the Union address, President...
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and...
Cancers are driven by unique genetic alterations, so what if we targeted these alterations to treat the cancer? It seems...
In the past couple of decades, progress against cancer has created a new generation of survivors. Today, more than...
The American Association for Cancer Research (AACR) is pleased to announce the Call for Abstracts for the AACR Annual...
Progress against cancer has been fueled not by a single discipline or a sole blockbuster discovery, but by incremental...
As the COVID-19 pandemic swept the globe this spring, the American Association for Cancer Research (AACR) launched a major...
A recap of the plenary sessions, cutting-edge science, clinical trials, and more covered by the AACR blog.
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
It’s that time of year when we reflect on the progress we made over the past 12 months –...
At the age of 40, Marlena Murphy was diagnosed with triple-negative breast cancer, an aggressive subtype that occurs twice...
The Global Scholar Alumni Committee reflects on their progress after the first year in helping the careers of young...
Insights from the AACR Cancer Disparities Progress Report 2024.
In an extraordinary turn of events, the American Association for Cancer Research (AACR) Annual Meeting 2020 kicked off Monday...
A major objective of former Vice President Joe Biden’s National Cancer Moonshot Initiative is breaking down silos and sharing...
Editor’s Note: Several prominent American Association for Cancer Research (AACR) leaders have shared their reactions to President Obama’s Jan....
The AACR Annual Meeting 2021 featured the theme “Discovery Science Driving Clinical Breakthroughs.” Indeed, over the course of two weeks,...
There has been a rapid expansion of technology in recent years, from artificial intelligence to intensive genetic sequencing to...
This past year has been a year of many “firsts” for the oncology community, with several revolutionary advances in...
Just over a month ago, the American Association for Cancer Research (AACR) held the first portion of its Annual...
Guest post by Hisham Hamadeh, PhD, and Shawn M. Sweeney, PhD Imagine a world where many of the decisions...
From a joyous opening performance from the Preservation Hall All-Stars to a closing plenary that highlighted the full spectrum...
Vice President Joe Biden spoke at the AACR Annual Meeting 2016 about the importance of breaking silos and promoting...
The abstract submitter is now open for the submission of clinical trial and late-breaking abstracts. The deadline for clinical...
IMPORTANT: PROFFERED PAPER PRESENTATION FORMAT All proffered papers that are accepted for poster or oral presentation at the AACR...